Skip to content
Catalyst

PapersPMID:35936217

Clinical Evidence of Acetyl-L-Carnitine Efficacy in the Treatment of Acute Ischemic Stroke: A Pilot Clinical Trial.

Oxidative medicine and cellular longevity2022The record ↗

findings
3
compound
1
endpoints
3
PMID:35936217
  1. Finding, moderate evidencelowersTumour necrosis factor alpha concentration
  2. Finding, moderate evidencelowersInterleukin-6 concentration
  3. Finding, moderate evidenceraisesTotal antioxidant capacity
Study, every finding
RCT · 3 days
Dose studied, every finding
1000 mg oral ALC three times per day for three consecutive days (nine doses); nasogastric tube if dysphagia
  • “After three days of the treatment protocol, also the serum levels of TNF- α, IL-6, and ICAM-1, as proinflammatory cytokines, decreased more in the ALC group than in the placebo group (p value = 0.04, 0.02, and 0.03, respectively).”
    • Population
      Adults with first-ever acute ischaemic stroke, onset under 24 hours, not candidates for reperfusion therapy, all receiving standard care; change over the 3-day treatment
    • Population
      Adults with first-ever acute ischaemic stroke, onset under 24 hours, not candidates for reperfusion therapy, all receiving standard care; change over the 3-day treatment
  • “Based on the results, 72 hours after the drug administration in the cases receiving ALC, serum levels of TAC, SOD, and GPx, as antioxidants biomarkers, were significantly higher than those in the placebo group (p value = 0.01, 0.02, and 0.01, respectively).”
    Population
    Adults with first-ever acute ischaemic stroke, onset under 24 hours, not candidates for reperfusion therapy, all receiving standard care; measured 72 hours after the first dose

Study record

Design
randomised controlled trial
Species
human
Population
patients with first-ever acute ischemic stroke, symptom onset under 24 hours, not candidates for thrombolytic therapy or mechanical thrombectomy
Participants
69
Comparator
placebo
Duration
3 days
Endpoints measured
23